| Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures R Vander Velde, N Yoon, V Marusyk, A Durmaz, A Dhawan, ... Nature communications 11 (1), 2393, 2020 | 85 | 2020 |
| Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia H Awada, A Durmaz, C Gurnari, A Kishtagari, M Meggendorfer, CM Kerr, ... Blood, The Journal of the American Society of Hematology 138 (19), 1885-1895, 2021 | 45 | 2021 |
| Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria C Gurnari, S Pagliuca, PH Prata, JE Galimard, LFB Catto, L Larcher, ... Journal of Clinical Oncology 41 (1), 132-142, 2023 | 41 | 2023 |
| Target-independent prediction of drug synergies using only drug lipophilicity K Yilancioglu, ZB Weinstein, C Meydan, A Akhmetov, I Toprak, A Durmaz, ... Journal of chemical information and modeling 54 (8), 2286-2293, 2014 | 38 | 2014 |
| Measuring competitive exclusion in non–small cell lung cancer N Farrokhian, J Maltas, M Dinh, A Durmaz, P Ellsworth, M Hitomi, ... Science Advances 8 (26), eabm7212, 2022 | 34 | 2022 |
| Identifying States of Collateral Sensitivity during the Evolution of Therapeutic Resistance in Ewing's Sarcoma JA Scarborough, E McClure, P Anderson, A Dhawan, A Durmaz, ... Iscience 23 (7), 2020 | 26 | 2020 |
| Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes T Kewan, W Bahaj, A Durmaz, M Aly, OD Ogbue, HE Carraway, ... Blood 141 (14), 1768-1772, 2023 | 22 | 2023 |
| Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases AM Baschnagel, S Kaushik, A Durmaz, S Goldstein, IM Ong, L Abel, ... Scientific Reports 11 (1), 2520, 2021 | 17 | 2021 |
| Personalized risk schemes and machine learning to empower genomic prognostication models in myelodysplastic syndromes H Awada, C Gurnari, A Durmaz, H Awada, S Pagliuca, V Visconte International Journal of Molecular Sciences 23 (5), 2802, 2022 | 12 | 2022 |
| Impact of immediate cryopreservation on the establishment of patient derived xenografts from head and neck cancer patients L Abel, A Durmaz, R Hu, C Longhurst, AM Baschnagel, D Wheeler, ... Journal of Translational Medicine 19 (1), 180, 2021 | 9 | 2021 |
| Molecular patterns identify distinct subclasses of myeloid neoplasia T Kewan, A Durmaz, W Bahaj, C Gurnari, L Terkawi, H Awada, OD Ogbue, ... Nature communications 14 (1), 3136, 2023 | 8 | 2023 |
| Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia W Bahaj, T Kewan, C Gurnari, A Durmaz, B Ponvilawan, I Pandit, ... Journal of Hematology & Oncology 16 (1), 91, 2023 | 7 | 2023 |
| Identifying states of collateral sensitivity during the evolution of therapeutic resistance in Ewing’s sarcoma. iScience. 2020 JA Scarborough, E McClure, P Anderson, A Dhawan, A Durmaz, ... | 7 | |
| Dose dependent evolutionary game dynamics modulate competitive release in cancer therapy N Farrokhian, J Maltas, P Ellsworth, A Durmaz, M Dinh, M Hitomi, ... bioRxiv 2020 (18.303966), 2020 | 6 | 2020 |
| Frequent subgraph mining of functional interaction patterns across multiple cancers A Durmaz, TAD Henderson, G Bebek BIOCOMPUTING 2021: Proceedings of the Pacific Symposium, 261-272, 2020 | 6 | 2020 |
| IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria C Gurnari, PH Prata, LFB Catto, A Durmaz, L Larcher, M Sebert, V Allain, ... Blood, The Journal of the American Society of Hematology 141 (25), 3122-3125, 2023 | 5 | 2023 |
| A clinically practicable approach to predict TP53 allelic configurations in myeloid neoplasia W Bahaj, T Kewan, C Gurnari, A Durmaz, BEN Ponvilawan, I Pandit, ... Blood 140 (Supplement 1), 2075-2077, 2022 | 5 | 2022 |
| Mutational patterns and clonal architecture of therapy-related acute myeloid Leukemia H Awada, T Kuzmanovic, A Kishtagari, J Durrani, A Durmaz, S Hong, ... Blood 134, 1405, 2019 | 5 | 2019 |
| Splenectomy outcomes in immune cytopenias: Treatment outcomes and determinants of response OD Ogbue, W Bahaj, T Kewan, R Ahmed, D Dima, N Willimas, A Durmaz, ... Journal of Internal Medicine 295 (2), 229-241, 2024 | 4 | 2024 |
| Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets M Mori, Y Kubota, A Durmaz, C Gurnari, C Goodings, V Adema, ... Leukemia 37 (10), 2082-2093, 2023 | 4 | 2023 |
